Details of the Drug

General Information of Drug (ID: DM2PYNR)

Drug Name
Phenindione
Synonyms
Athrombon; Bindan; Cronodione; Danedion; Danilon; Danilone; Diadilan; Dindevan; Dineval; Diophindane; Emandion; Emandione; Eridione; Fenhydren; Fenilin; Fenindion; Fenindiona; Hedulin; Hemolidione; Indema; Indion; Indon; Phenhydren; Phenillin; Phenindionum; Phenylen; Phenylin; Phenylindanedione; Phenylindione; Phenyline; Phenyllin; Pindione; Rectadione; Theradione; Thrombasal; Tromazal; Trombol; Boots Brand of Phenindione; Goldshield Brand of Phenindione; Merck Lipha Sante Brand of Phenindione; P1029; P26406_ALDRICH; Fenindiona [INN-Spanish]; Hedulin (TN); Phenindione (INN); Phenindione [INN:BAN]; Phenindionum [INN-Latin]; 2 Phenyl 1,3 indandione; 2-Fenyloindandion-1,3; 2-Fenyloindandion-1,3 [Polish]; 2-Phenyl-1,3-diketohydrindene; 2-Phenyl-1,3-indandione; 2-Phenyl-1,3-indanedione; 2-Phenyl-1H-indene-1,3(2H)-dione; 2-Phenylindan-1,3-dione; 2-Phenylindandione; 2-phenyl-1,3(2H)-Indenedione; 2-phenyl-2,3-dihydro-1H-indene-1,3-dione; 2-phenylindene-1,3-dione
Indication
Disease Entry ICD 11 Status REF
Coagulation defect 3B10.0 Approved [1]
Pulmonary embolism BB00 Approved [1]
Therapeutic Class
Anticoagulants
Affected Organisms
Humans and other mammals
ATC Code
B01AA02: Phenindione
B01AA: Vitamin K antagonists
B01A: ANTITHROMBOTIC AGENTS
B01: ANTITHROMBOTIC AGENTS
B: BLOOD AND BLOOD FORMING ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 222.24
Logarithm of the Partition Coefficient (xlogp) 2.9
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is absorbed slowly from the gastrointestinal tract []
Bioavailability
97% of drug becomes completely available to its intended biological destination(s) [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 5 - 10 hours [3]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.98341 micromolar/kg/day [4]
Chemical Identifiers
Formula
C15H10O2
IUPAC Name
2-phenylindene-1,3-dione
Canonical SMILES
C1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
InChI
InChI=1S/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H
InChIKey
NFBAXHOPROOJAW-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4760
ChEBI ID
CHEMBL8066
CAS Number
83-12-5
UNII
5M7Y6274ZE
DrugBank ID
DB00498
TTD ID
D08FTG
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vitamin K epoxide reductase complex 1 (VKORC1) TTEUC8H VKOR1_HUMAN Inhibitor [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Vitamin K epoxide reductase complex subunit 1 OTOJNJRD VKOR1_HUMAN Gene/Protein Processing [6]
Vitamin K epoxide reductase complex subunit 1-like protein 1 OT7QSEWT VKORL_HUMAN Gene/Protein Processing [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6838).
2 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. Rev Med Suisse. 2007 Sep 12;3(124):2030, 2033-4, 2036.
6 VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites. Blood Adv. 2018 Mar 27;2(6):691-702.